라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etoricoxib teva 120 mg apvalkotās tabletes
teva b.v., netherlands - etorikoksibs - apvalkotā tablete - 120 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etoricoxib zentiva 90 mg apvalkotās tabletes
zentiva, k.s., czech republic - etorikoksibs - apvalkotā tablete - 90 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etoricoxib zentiva 60 mg apvalkotās tabletes
zentiva, k.s., czech republic - etorikoksibs - apvalkotā tablete - 60 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etoricoxib zentiva 120 mg apvalkotās tabletes
zentiva, k.s., czech republic - etorikoksibs - apvalkotā tablete - 120 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etidylan 90 mg apvalkotās tabletes
g.l. pharma gmbh, austria - etorikoksibs - apvalkotā tablete - 90 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etidylan 120 mg apvalkotās tabletes
g.l. pharma gmbh, austria - etorikoksibs - apvalkotā tablete - 120 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
etidylan 60 mg apvalkotās tabletes
g.l. pharma gmbh, austria - etorikoksibs - apvalkotā tablete - 60 mg
유럽 연합 -
라트비아어 -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - multiple mieloma - antineoplastiski līdzekļi - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
prostarinol 5 mg apvalkotās tabletes
olainfarm, as, latvia - finasterīds - apvalkotā tablete - 5 mg
라트비아 -
라트비아어 -
Zāļu valsts aģentūra
thromboreductin 0,5 mg cietās kapsulas
aop orphan pharmaceuticals gmbh, austria - anagrelīda hidrohlorīds - kapsula, cietā - 0,5 mg